These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34278933)

  • 1. The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies.
    Attili I; Del Re M; Guerini-Rocco E; Crucitta S; Pisapia P; Pepe F; Barberis M; Troncone G; Danesi R; de Marinis F; Malapelle U; Passaro A
    Expert Rev Mol Diagn; 2021 Aug; 21(8):757-766. PubMed ID: 34278933
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
    Kohsaka S; Petronczki M; Solca F; Maemondo M
    Future Oncol; 2019 Feb; 15(6):637-652. PubMed ID: 30404555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.
    Lim ZF; Ma PC
    J Hematol Oncol; 2019 Dec; 12(1):134. PubMed ID: 31815659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
    Suda K; Murakami I; Obata K; Sakai K; Fujino T; Koga T; Ohara S; Hamada A; Soh J; Nishio K; Mitsudomi T
    Lung Cancer; 2020 Oct; 148():100-104. PubMed ID: 32861140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
    Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
    Lee DH
    Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
    Boyle TA; Quinn GP; Schabath MB; Muñoz-Antonia T; Saller JJ; Duarte LF; Hair LS; Teer JK; Chiang DY; Leary R; Wong CC; Savchenko A; Singh AP; Charette L; Mendell K; Gorgun G; Antonia SJ; Chiappori AA; Creelan BC; Gray JE; Haura EB
    Cancer Med; 2020 Jan; 9(1):225-237. PubMed ID: 31747139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.
    Piotrowska Z; Sequist LV
    JAMA Oncol; 2016 Jul; 2(7):948-54. PubMed ID: 27196961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ricordel C; Friboulet L; Facchinetti F; Soria JC
    Ann Oncol; 2018 Jan; 29(suppl_1):i28-i37. PubMed ID: 29462256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.
    Liu WJ; Du Y; Wen R; Yang M; Xu J
    Pharmacol Ther; 2020 Feb; 206():107438. PubMed ID: 31715289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the EGFR T790M mutation in non-small-cell lung cancer.
    Normanno N; Maiello MR; Chicchinelli N; Iannaccone A; Esposito C; De Cecio R; D'alessio A; De Luca A
    Expert Opin Ther Targets; 2017 Feb; 21(2):159-165. PubMed ID: 28002980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.